Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Kumar, Shaji K  [Clear All Filters]
Journal Article
Sidana S, M Sidiqi H, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, et al. 15 Year Overall Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis. Am J Hematol. 2019.
M Sidiqi H, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, et al. Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant. 2018.
Cordes S, Gertz MA, Buadi FK, Lin Y, Lacy MQ, Kapoor P, Kumar SK, McCurdy A, Dispenzieri A, Dingli D, et al. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagul Fibrinolysis. 2015.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomise. Lancet Oncol. 2020.
Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, et al. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020.
Saleh ASAl, M Sidiqi H, Lee J, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, et al. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplant. 2020.
Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016.
Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, S Rajkumar V, Go RS, Leung N, et al. Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation. Am J Hematol. 2016.
Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, et al. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2013.
Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016.
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, et al. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019.
Saleh ASAl, M Sidiqi H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kourelis TV, et al. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Saleh ASAl, Parmar HV, Vaxman I, Visram A, M Sidiqi H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, et al. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2020.